HORMONE receptor positive breast cancerThis article provides a comprehensive overview of recent advancements in the treatment of hormonal receptor positive (HR ) breast cancer. It discusses various treatment options such as CDK4/6 inhibitors, PI3 kinase inhibitors, antibody drug ...
[4].Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, et al. Firstline treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positivemetastatic breast cancer from registHER. Oncologist 2013;18:501–10.[5].Rimawi M, Ferrero JM, de la Ha...
[18]Li TF, Shan Z, Lin Y, et al. Sequential versus concurrent use of chemotherapy and endocrinetherapy in the adjuvant treatment of ER-positive breast cancer: A systematicreview and Bayesian network meta-analysis. 2019 ASCO. e12040.
[4]Hortobagyi GN,Stemmer SM,Burris HA,et al.Overall survival(OS)results from the phase III MONALEESA-2(ML-2)trial of postmenopausal patients(pts)with hormone receptor positive/human epidermal growth factor receptor 2 negative(HR+/HER2−)advanced breast cancer(ABC)treated with endocrine therapy(...
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 (2016) ...
【2】Tianfu Li, Zhen Shan,Ying Lin, et al. Sequential versus concurrent use of chemotherapy and endocrinetherapy in the adjuvant treatment of ER-positive breast cancer: A systematicreview and Bayesian network meta-analysis. 2019 ASCO 仅供医疗专业人士参考 ...
7.Tianfu Li, Zhen Shan, Liang Yu, et al. Sequential versus concurrent use of chemotherapy and endocrine therapy in the adjuvant treatment of ER-positive breast cancer: A systematic review and Bayesian network meta-analysis[J...
2024年5月,复旦大学附属肿瘤医院吴炅教授团队在《Cancer Treatment Reviews》(影响因子为11.8)发表了一篇综述,题为《Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use...
In this special edition of the “Oncology Peer Review On-The-Go” podcast, CancerNetwork spoke with Reshma L. Mahtani, DO, about genomic testing to optimize treatment outcomes in HR-positive breast cancer. As part of its OncView video series, CancerNetwork spoke with Reshma L. Ma...
itive Breast Cancer HR-Positive Breast CancerHR-Positive Breast CancerHarold J. Burstein